会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Crystalline polymorphs of clopidogrel
    • 氯吡格雷的结晶多晶型物
    • US07897613B2
    • 2011-03-01
    • US10571419
    • 2004-09-09
    • Ramakrishnan ArulAjay Singh RawatMaheshkumar GadakarRajesh RaoAbhinay PiseJason Gray
    • Ramakrishnan ArulAjay Singh RawatMaheshkumar GadakarRajesh RaoAbhinay PiseJason Gray
    • C07D495/04A61K31/4365A61P7/02
    • C07D495/04
    • The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1).
    • 本发明涉及血小板聚集抑制剂(+) - (S) - 甲基-2-(2-氯苯基) - (6,7-二氢-4H-噻吩并[3,2-c]吡啶-3-基) (1),以溴化氢的形式,被鉴定为多晶型形式1,2和3.本发明还涉及制备这些形式的方法,包含这些形式的药物组合物和用于 这种形式和组成。 药物组合物可特别用于抑制血小板聚集或治疗,预防或控制血栓形成,动脉粥样硬化血栓形成,动脉粥样硬化血栓形成事件,缺血性中风,心肌梗塞,非Q波心肌梗塞,动脉粥样硬化,外周动脉疾病或 不稳定型心绞痛 本发明还涉及治疗所述疾病的方法。 公式1)。
    • 2. 发明申请
    • Novel Crystalline Polymorphs of Clopidogrel
    • 氯吡格雷的新型结晶多晶型物
    • US20070281964A1
    • 2007-12-06
    • US10571419
    • 2004-09-09
    • Ramakrishnan ArulAjay RawatMaheshkumar GadakarRajesh RaoAbhinay PiseJason Gray
    • Ramakrishnan ArulAjay RawatMaheshkumar GadakarRajesh RaoAbhinay PiseJason Gray
    • A61K31/4365A61P7/02C07D495/04
    • C07D495/04
    • The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1).
    • 本发明涉及血小板聚集抑制剂(+) - (S) - 甲基-2-(2-氯苯基) - (6,7-二氢-4H-噻吩并[3,2-c]吡啶-3-基) (1),以溴化氢的形式,被鉴定为多晶型形式1,2和3.本发明还涉及制备这些形式的方法,包含这些形式的药物组合物和用于 这种形式和组成。 药物组合物可特别用于抑制血小板聚集或治疗,预防或控制血栓形成,动脉粥样硬化血栓形成,动脉粥样硬化血栓形成事件,缺血性卒中,心肌梗死,非Q波心肌梗塞,动脉粥样硬化,外周动脉疾病或 不稳定型心绞痛 本发明还涉及治疗所述疾病的方法。 公式1)。